UZ Brussel HRMC Registry of Brugada Syndrome

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorUniversitair Ziekenhuis Brussel

About this trial

The monocentric UZB registry for Brugada registry is intended to collect all data on patients affected by Brugada syndrome at UZ Brussel hospital (UZB).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Brugada syndrome diagnosis

Disqualifiers

Other diagnosis different from Brugada syndrome

Trial population

Brugada syndrome patients diagnosed following current guidelines: (Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:2793-2867.) Both Brugada spontaneous type 1 and ajmaline induced will be included.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • No intervention because it is a patient registry

    Other intervention

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Ventricular arrhythmias

Composite of: sudden cardiac death, aborted sudden cardiac death, ventricular fibrillation, sustained ventricular tachycardia, ICD appropriate therapy

Time frame
through study completion, an average of 10 year
2

Atrial fibrillation

Atrial fibrillation occurrence

Time frame
through study completion, an average of 10 year
3

Death for any cause

Death for any cause

Time frame
through study completion, an average of 10 year
4

Cardiovascular death

Death for cardiovascular cause

Time frame
through study completion, an average of 10 year

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.